Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights

Net revenue for third quarter of 2021 increased 123% year-over-year to $21.1 million, a quarterly record Journey Medical Corporation, a Fortress partner company, launched its $35.2 million initial public offering AstraZeneca acquired Caelum Biosciences; Fortress received $56.9 million upfront1 Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to be initiated in the fourth quarter of 2021 Top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma expected around year-end 2021

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here